Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jan 24;28(7):1422–1432. doi: 10.1158/1078-0432.CCR-21-3764

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

©2022 The Authors; Published by the American Association for Cancer Research

This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.

PMC Copyright notice

Figure 1. Incidence of the IR and AR to vismodegib in the studied cohort of 148 locally advanced BCC. A, Vismodegib treatment duration and diagnostic of resistance. B, Cumulative incidence of vismodegib discontinuation for IR, AR, and vismodegib discontinuation (VD) without resistance. — Incidence of the IR and AR to vismodegib in the studied cohort of 148 locally advanced BCC. A, Vismodegib treatment duration and diagnostic of resistance. B, Cumulative incidence of vismodegib discontinuation for IR, AR, and vismodegib discontinuation (VD) without resistance.